ICD-10 Code for Ordering Probiotics During Antibiotic Therapy
Use Z79.2 (Long term [current] use of antibiotics) as the primary ICD-10 code when ordering probiotics for patients receiving antibiotic therapy as prophylaxis against antibiotic-associated complications.
Rationale and Clinical Context
The evidence supports using probiotics prophylactically in patients receiving antibiotics, particularly to prevent Clostridioides difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Prophylactic probiotics may be considered for inpatients receiving antibiotics during high-risk periods 1.
Key Supporting Evidence
For CDI Prevention: Specific probiotic strains including Saccharomyces boulardii I-745, Lactobacillus casei DN114001, and certain multi-strain combinations have demonstrated efficacy in preventing CDI when given alongside antibiotics 1.
Absolute Risk Reduction: Recent systematic review data shows probiotics may result in a 1.6% absolute risk reduction in CDAD (from 3.2% to 1.6%), representing a 50% relative risk reduction 2.
Safety Profile: Probiotics probably result in fewer adverse events compared to placebo (10.9% vs 12.2%), with common side effects limited to mild gastrointestinal symptoms like abdominal cramping and flatulence 2.
Alternative ICD-10 Codes to Consider
Depending on the specific clinical scenario, you may also use:
- K94.19 (Other complications of gastrostomy) - if the patient has enteral access
- Z87.19 (Personal history of other diseases of the digestive system) - if prior history of CDI
- K52.9 (Noninfective gastroenteritis and colitis, unspecified) - if prophylaxis for diarrhea is the primary concern
Critical Caveats and Contraindications
Do NOT use probiotics in immunocompromised patients 1. This is a firm contraindication due to rare but serious risk of bacteremia or fungemia. The guidelines explicitly state: "Probiotics should not be used in immunocompromised patients" 1.
Strain-Specific Considerations
Not all probiotics are equally effective - efficacy is both strain-specific and disease-specific 1, 3. When documenting, consider specifying the strain if known, as this impacts clinical appropriateness:
- For CDI prevention: S. boulardii I-745, L. casei DN114001, or specific multi-strain combinations 1
- For general AAD prevention: Various Lactobacillus and Bifidobacterium combinations 2
Clinical Setting Matters
The baseline risk of CDI in your setting influences the number needed to treat. In low-risk settings (<2% baseline CDI rate), approximately 65 patients need treatment to prevent one case of CDAD 2. Hospital outbreak settings or high-risk periods warrant stronger consideration for prophylactic probiotics 1.
Documentation Best Practices
When ordering probiotics with Z79.2:
- Document the specific antibiotic being used
- Note the duration of antibiotic therapy
- Specify if the patient is in a high-risk category (e.g., hospital outbreak, prior CDI history)
- Confirm the patient is NOT immunocompromised
- Consider documenting the specific probiotic strain if available
This approach aligns with the evidence showing that mandatory indications within antibiotic orders show better congruence with charted diagnosis than ICD-10 codes alone 4, supporting clear documentation of the prophylactic intent.